Nkarta (NASDAQ: NKTX)
Nkarta Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Nkarta Company Info
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
News & Analysis
Why Nkarta Stock Is Soaring Today
One analyst is now more bullish about this clinical-stage biotech stock.
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.